Quadrant wins EUA for COVID-19 saliva test September 24, 2020 -- Quadrant Biosciences has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its Clarifi COVID-19 test kit.
United Airlines launches pilot COVID-19 testing program September 24, 2020 -- United Airlines has announced a pilot COVID-19 testing program for travelers in which customers traveling on United from San Francisco International Airport to Hawaii will have the option of taking a rapid COVID-19 test at the airport or a self-collected, mail-in test ahead of the trip.
BD seeks FDA OK to use more samples with HPV test September 23, 2020 -- Becton Dickinson (BD) has asked the U.S. Food and Drug Administration (FDA) to make the ThinPrep Pap Test PreservCyt Solution vial an approved sample for its Onclarity HPV Assay.
Promega to further develop OncoMate MSI assay September 22, 2020 -- Promega announced that it plans to further develop its OncoMate microsatellite instability (MSI) assay as a companion diagnostic test for Incyte's anti-PD-1 drug candidate for endometrial cancer, retifanlimab.
Holy Grail: Ilumina nabs cancer testing firm in $8B deal September 21, 2020 -- Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing (NGS) technology, data science, and machine learning to identify cancer signals in blood samples.
Hoth, GW partner to develop mobile COVID-19 test September 21, 2020 -- Clinical-stage biopharmaceutical company Hoth Therapeutics and George Washington University (GW) have partnered to create a device that allows health professionals to diagnose COVID-19 with a mobile device.
Siemens donates $500K to Testing for America September 21, 2020 -- Siemens Healthineers and the Siemens Foundation have partnered with Testing for America to donate $500,000 in funding and COVID-19 testing to historically Black colleges and universities across the country.
Qiagen closes NeuMoDx deal September 18, 2020 -- Qiagen has acquired the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular for $248 million in cash. The deal rounds out Qiagen's portfolio of automated molecular testing based on polymerase chain reaction technology.